Library of Congress. Congressional Research Service.
Abstract
This report identifies and analyzes the patent law aspects of the current avian
influenza drug situation. First, the report explains the role that patent rights have
played in affecting the availability of Tamiflu. Second, the report examines options
for increasing the drug’s production, including the possibility of governments
abrogating Roche’s patent rights by issuing compulsory licenses to other drug
companies to manufacture generic versions of Tamiflu without Roche’s consent
